Skip to main content

FDA Drug Recalls

Every FDA drug enforcement recall Public Health Trace has on record, republished from openFDA's official drug enforcement database. See Health Alerts for current, active recalls alongside outbreaks and advisories.

Drug recall information is sourced from the FDA's structured openFDA Enforcement Reports. Newly announced recalls may appear on FDA.gov before they become available in the structured dataset. See Methodology for how Public Health Trace imports and refreshes this data.

Filters
Recall details
Location
Date range
Clear filters

Showing 1,041–1,060 of 18,047 drug recalls

Drug Recall Ongoing Historical recordClass II

Lorazepam Injection, USP, 2 mg/mL, 25 x 1mL vials/carton, Rx Only, Manufactured by: Hikma Berkeley Heights, NJ 07922, NDC# 0641-6044-25

by Hikma Pharmaceuticals USA Inc.

Reason
Failed Impurities/Degradation Specifications: An out-of-Specification for total related compounds
Recall initiated
July 22, 2025
Reported by FDA
August 6, 2025
Distribution
Distributed Nationwide in the USA

View recall →

Drug Recall Ongoing Historical recordClass II

Sucralfate Tablets, USP 1 gram, packaged in a) 100-count bottles NDC 29033-0003-01, and b) 500-count bottles, NDC 29033-0003-05), Rx Only, Manufactured by: Nostrum Laboratories, Inc., Kansas City, MO 64120.

by Nostrum Laboratories, Inc.

Reason
CGMP Deviations: The recalling firm filed for Chapter 11 in September 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess, rendering the products adulterated.
Recall initiated
July 11, 2025
Reported by FDA
August 6, 2025
Distribution
nationwide within the United States

View recall →

Drug Recall Ongoing Historical recordClass II

Cinacalcet Tablets 90 mg, 30-count bottles, Rx only, Manufactured by: Strides Pharma Science Ltd. Puducherry, India; Distributed by: Strides Pharma Inc. East Brunswick, NJ 08816, NDC 64380-885-04

by Strides Pharma, Inc.

Reason
Failed Dissolution Specifications.
Recall initiated
July 9, 2025
Reported by FDA
August 6, 2025
Distribution
Product was distributed nationwide within the United States

View recall →

Drug Recall Ongoing Historical recordClass II

Bicillin L-A (penicillin G benzathine injectable suspension), 2,400,000 units per 4 mL, 4ml-vial, Rx Only, Distributed by Pfizer Inc., New York, NY 10001, Made in Austria, Carton NDC- 60793-702-10 , Syringe NDC-60793-702-04

by Pfizer Inc.

Reason
CGMP Deviations; particulates identified during visual inspection
Recall initiated
July 10, 2025
Reported by FDA
August 6, 2025
Distribution
Nationwide in the USA

View recall →

Drug Recall Ongoing Historical recordClass II

Bicillin L-A (penicllin G benzathine injectable suspension), 1,200,000 units per 2 mL, 2 mL-vial, Rx Only, Distributed by Pfizer Inc., New York, NY 10001. Made in Austria, Carton NDC - 60793-701-10, Syringe NDC - 60793-701-02

by Pfizer Inc.

Reason
CGMP Deviations; particulates identified during visual inspection
Recall initiated
July 10, 2025
Reported by FDA
August 6, 2025
Distribution
Nationwide in the USA

View recall →

Drug Recall Ongoing Historical recordClass II

Timolol Maleate Ophthalmic Solution USP, 0.5%, Sterile, 5mL bottles, Rx only, Manufactured by: FDC Limited, Waluj, Aurangabad, Maharashtra, India, Distributed by: Rising Pharmaceuticals Inc, New Jersey, NDC 64980-514-05.

by FDC Limited

Reason
Defective Container: spike of the cap becomes lodged in the nozzle of the product bottle.
Recall initiated
July 5, 2025
Reported by FDA
August 6, 2025
Distribution
U.S Nationwide.

View recall →

Drug Recall Completed Historical recordClass II

Amlodipine and Benazepril HCl Capsules USP 2.5 mg/10 mg, 100 Capsules bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL, 34108, United States, Manufactured by: Lupin Limited, Goa 103 722, INDIA, NDC 68180-755-01.

by Lupin Pharmaceuticals Inc.

Reason
Labeling: Incorrect or Missing Lot and/or Exp Date: released with wrong expiry date as Feb.2027 instead of Jan.2027
Recall initiated
July 2, 2025
Reported by FDA
August 6, 2025
Distribution
Nationwide in the US

View recall →

Drug Recall Ongoing Historical recordClass II

Budesonide Inhalation Suspension, 0.5mg/2ml, 30 single-dose ampules per carton, five per pouch, RX Only, Manufactured by: Cipla Ltd. Indore SEZ, Pithampur, India. Manufactured for: Ciple USA, Inc. 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC# 69097-319-86 (pouch), 69097-319-87 (carton)

by Cipla USA, Inc.

Reason
Lack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule.
Recall initiated
June 30, 2025
Reported by FDA
July 30, 2025
Distribution
Distributed Nationwide in the USA

View recall →

Drug Recall Ongoing Historical recordClass II

BENLYSTA (belimumab) for injection, 400 mg/20 mL vial, Rx only, NDC 49401-102-01, GSK.

by Mckesson Medical-Surgical Inc. Corporate Office

Reason
CGMP Deviations; potential temperature excursions due to transit delays
Recall initiated
April 21, 2025
Reported by FDA
July 30, 2025
Distribution
Within the U.S - OH, VA, FL.

View recall →

Drug Recall Ongoing Historical recordClass II

EVENITY, (romosozumab -aqqg) injection, 105mg/1.17 mL, For Subcutaneous Use Only, Rx Only, Manufactured by: Amgen Inc., Thousand Oaks, CA 91320, NDC 55513-880-02.

by Mckesson Medical-Surgical Inc. Corporate Office

Reason
CGMP Deviations; potential temperature excursions due to transit delays
Recall initiated
April 21, 2025
Reported by FDA
July 30, 2025
Distribution
Within the U.S - OH, VA, FL.

View recall →

Drug Recall Ongoing Historical recordClass II

PROLIA (denosumab), injection, 60mg/mL, For Subcutaneous Use Only, Rx Only, Manufactured by: Amgen Inc., Thousand Oaks, CA 91320, NDC 55513-710-21

by Mckesson Medical-Surgical Inc. Corporate Office

Reason
CGMP Deviations; potential temperature excursions due to transit delays
Recall initiated
April 21, 2025
Reported by FDA
July 30, 2025
Distribution
Within the U.S - OH, VA, FL.

View recall →

Drug Recall Terminated Historical recordClass II

clomiPRAMINE Hydrochloride Capsules USP 25 mg, 100 count bottles, 5801 Pelican Bay Boulevard, Suite 500, Naples, Florida 34108, NDC# 68180-492-01

by Lupin Pharmaceuticals Inc.

Reason
Failed Impurities/Degradation Specifications: an out of specification result observed in degradation product test (any unspecified degradation product) during retention sample testing at expiry.
Recall initiated
June 27, 2025
Reported by FDA
July 30, 2025
Distribution
Nationwide.

View recall →

Drug Recall Completed Historical recordClass III

Tropicamide-Proparacaine-Phenylephrine-Ketorolac, Sterile Ophthalmic Solution, 1% 0.5% 2.5% 0.5%, 5mL, 2x5ML vial per carton, Rx Only, Imprimis NJOF, LLC, 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852, NDC 71384-733-05.

by Imprimis NJOF, LLC

Reason
Sub-Potent Drug: Subpotent assay results during stability testing.
Recall initiated
July 9, 2025
Reported by FDA
July 30, 2025
Distribution
Nationwide in the USA

View recall →

Drug Recall Completed Historical recordClass II

Epinephrine Lidocaine HCL, 0.25mg/mL and 7.5 mg/mL, 20x1 mL Vials per carton, Rx Only, Imprimis NJOF, 1705 Route 46 West, Unit 6B Ledgewood, NJ, 07852 NDC: 71384-641-01

by Imprimis NJOF, LLC

Reason
Sub-Potent Drug: Subpotent assay results during stability testing.
Recall initiated
July 9, 2025
Reported by FDA
July 30, 2025
Distribution
Nationwide in the USA

View recall →

Drug Recall Ongoing Historical recordClass II

Shave and Skincare Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant/Deodorant, 1.8 oz./ 53 mL, A.P Deauville, LLC, PA 18040, NDC# 42913-040-00 UPC Code 815195018224

by A.P. Deauville, LLC

Reason
CGMP Deviations
Recall initiated
July 10, 2025
Reported by FDA
July 23, 2025
Distribution
U.S. Nationwide

View recall →

Drug Recall Ongoing Historical recordClass II

Beauty & Skincare Power Stick original nourishing invisible protection roll-on Antiperspirant/Deodorant Spring Fresh, 1.8 oz./53 mL, A.P Deauville, LLC, PA 18040, NDC# 42913-039-00, UPC Code 815195018194

by A.P. Deauville, LLC

Reason
CGMP Deviations
Recall initiated
July 10, 2025
Reported by FDA
July 23, 2025
Distribution
U.S. Nationwide

View recall →

Drug Recall Ongoing Historical recordClass II

Power Stick for her PH Balanced Roll-On Antiperspirant Deodorant with Powder Fresh Scent, 1.8 oz./53 mL, A.P Deauville, LLC, PA 18040, NDC# 42913-038-00, UPC Code 815195019313

by A.P. Deauville, LLC

Reason
CGMP Deviations
Recall initiated
July 10, 2025
Reported by FDA
July 23, 2025
Distribution
U.S. Nationwide

View recall →

Drug Recall Ongoing Historical recordClass II

Rizatriptan Benzoate Tablets, USP, 10 mg, 18 (3x6) Unit Dose Tablets, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories LLC, Parsippany, NJ 07054, NDC 67877-262-18

by Ascend Laboratories, LLC

Reason
CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.
Recall initiated
July 9, 2025
Reported by FDA
July 23, 2025
Distribution
US Nationwide.

View recall →

Drug Recall Ongoing Historical recordClass II

Rizatriptan Benzoate Tablets, USP, 5 mg, 18 (3x6) Unit Dose Tablets, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories LLC, Parsippany, NJ 07054, NDC 67877-261-18

by Ascend Laboratories, LLC

Reason
CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.
Recall initiated
July 9, 2025
Reported by FDA
July 23, 2025
Distribution
US Nationwide.

View recall →

Drug Recall Ongoing Historical recordClass II

Lisinopril and Hydrochlorothiazide Tablets USP 20mg/12.5mg, 100-count bottles, Rx only, Mfg for: Lupin Pharmaceuticals, Inc. Baltimore, MD 21202, Manufactured by: Lupin Limited Nagpur-441 108, INDIA, NDC 68180-519-01

by Lupin Pharmaceuticals Inc.

Reason
Product Mix Up: This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg.
Recall initiated
June 20, 2025
Reported by FDA
July 23, 2025
Distribution
Product was distributed nationwide within the United States.

View recall →

Data last updated:

This information is republished from FDA's Recall Enterprise System through openFDA. Public Health Trace does not verify or supplement it, is not affiliated with the FDA, and does not provide medical advice -- always follow the guidance of your pharmacist, physician, or the recalling company for any medication you take. Read the full medical disclaimer.

Reconnecting to the server…

We lost the connection to the server.

Your session has expired.